Showing results (51-60 of 261) with videos related to
Sort By:
Pageof 27
Blood Advances|January 10, 2020
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J Frigault, Philippe Armand, Robert A Redd, et al.Blood Advances|November 18, 2022
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W Merryman, Robert A Redd, Eleanor Taranto, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphomaJames M Cleary, Scott Rodig, Paul M Barr, et al.Journal of Medical Economics|March 31, 2021
Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United StatesXiaoqin Yang, François Laliberté, Guillaume Germain, et al.The Oncologist|February 22, 2021
Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.SXiaoqin Yang, François Laliberté, Guillaume Germain, et al.Blood|January 12, 2017
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphomaReid W Merryman, Haesook T Kim, Pier Luigi Zinzani, et al.The Oncologist|April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaReid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.Blood Advances|June 20, 2020
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failurePhilippe Armand, John Kuruvilla, Jean-Marie Michot, et al.Blood|August 31, 2016
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapyBruce D Cheson, Stephen Ansell, Larry Schwartz, et al.Blood|January 20, 2007
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantationPhilippe Armand, Haesook T Kim, Corey S Cutler, et al.Pageof 27